113 related articles for article (PubMed ID: 7873456)
41. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Cristofanilli M; Valero V; Mangalik A; Royce M; Rabinowitz I; Arena FP; Kroener JF; Curcio E; Watkins C; Bacus S; Cora EM; Anderson E; Magill PJ
Clin Cancer Res; 2010 Mar; 16(6):1904-14. PubMed ID: 20215537
[TBL] [Abstract][Full Text] [Related]
42. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.
Dowsett M; Doody D; Miall S; Howes A; English J; Coombes RC
Breast Cancer Res Treat; 1999 Jul; 56(1):25-34. PubMed ID: 10517340
[TBL] [Abstract][Full Text] [Related]
43. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
44. 4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer.
Coombes RC; Hughes SW; Dowsett M
Eur J Cancer; 1992; 28A(12):1941-5. PubMed ID: 1419285
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics and metabolism of formestane in breast cancer patients.
Lønning PE; Geisler J; Johannessen DC; Gschwind HP; Waldmeier F; Schneider W; Galli B; Winkler T; Blum W; Kriemler HP; Miller WR; Faigle JW
J Steroid Biochem Mol Biol; 2001 Apr; 77(1):39-47. PubMed ID: 11358673
[TBL] [Abstract][Full Text] [Related]
46. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
47. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
Bernhard J; Thürlimann B; Schmitz SF; Castiglione-Gertsch M; Cavalli F; Morant R; Fey MF; Bonnefoi H; Goldhirsch A; Hürny C
J Clin Oncol; 1999 Jun; 17(6):1672-9. PubMed ID: 10561203
[TBL] [Abstract][Full Text] [Related]
48. [Aromatase inhibitors--new possibilities in treatment of breast carcinoma].
Friedrichs K; Jänicke F
Praxis (Bern 1994); 1998 Apr; 87(17):584-8. PubMed ID: 9623325
[TBL] [Abstract][Full Text] [Related]
49. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
Younus J; Vandenberg TA
Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
[TBL] [Abstract][Full Text] [Related]
50. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer.
Murray R; Pitt P
Breast Cancer Res Treat; 1995 Sep; 35(3):249-53. PubMed ID: 7579495
[TBL] [Abstract][Full Text] [Related]
51. Aromatase inhibitors and the treatment of breast cancer.
Brodie AM; Wing LY; Goss P; Dowsett M; Coombes RC
J Steroid Biochem; 1986 Jan; 24(1):91-7. PubMed ID: 3702431
[TBL] [Abstract][Full Text] [Related]
52. The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers.
Martinetti A; Ferrari L; Celio L; Mariani L; Miceli R; Zilembo N; Di Bartolomeo M; Toffolatti L; Pozzi P; Seregni E; Bombardieri E; Bajetta E
J Steroid Biochem Mol Biol; 2000 Dec; 75(1):65-73. PubMed ID: 11179910
[TBL] [Abstract][Full Text] [Related]
53. Aromatase, its inhibitors and their use in breast cancer treatment.
Brodie AM
Pharmacol Ther; 1993 Dec; 60(3):501-15. PubMed ID: 8073072
[TBL] [Abstract][Full Text] [Related]
54. Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione.
Stein RC; Dowsett M; Hedley A; Davenport J; Gazet JC; Ford HT; Coombes RC
Cancer Chemother Pharmacol; 1990; 26(1):75-8. PubMed ID: 2322991
[TBL] [Abstract][Full Text] [Related]
55. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.
Coombes RC; Goss P; Dowsett M; Gazet JC; Brodie A
Lancet; 1984 Dec; 2(8414):1237-9. PubMed ID: 6150277
[TBL] [Abstract][Full Text] [Related]
56. Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane.
Martinetti A; Bajetta E; Seregni E; Zilembo N; Ferrari L; Noberasco C; Massaron S; Rimassa L; Bombardieri E
Tumour Biol; 1997; 18(4):197-205. PubMed ID: 9218004
[TBL] [Abstract][Full Text] [Related]
57. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.
Geisler J; Johannessen DC; Anker G; Lønning PE
Eur J Cancer; 1996 May; 32A(5):789-92. PubMed ID: 9081355
[TBL] [Abstract][Full Text] [Related]
58. Second-generation aromatase inhibitors.
Bajetta E; Zilembo N; Noberasco C
Tumori; 1995; 81(2):77-80. PubMed ID: 7778222
[No Abstract] [Full Text] [Related]
59. Effect of two-4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer.
Ferrari L; Zilembo N; Bajetta E; Buzzoni R; Noberasco C; Martinetti A; Celio L; Galante E; Orefice S; Cerrotta AM
Breast Cancer Res Treat; 1994; 30(2):127-32. PubMed ID: 7949210
[TBL] [Abstract][Full Text] [Related]
60. Trilostane in advanced breast cancer.
Puddefoot JR; Barker S; Vinson GP
Expert Opin Pharmacother; 2006 Dec; 7(17):2413-9. PubMed ID: 17109615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
